- Home
- BYRN vs QURE Comparison
BYRN vs QURE Comparison
Compare BYRN & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYRN
- QURE
- Stock Information
- Founded
- BYRN 2005
- QURE 1998
- Country
- BYRN United States
- QURE Netherlands
- Employees
- BYRN N/A
- QURE N/A
- Industry
- BYRN Industrial Machinery/Components
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- BYRN Miscellaneous
- QURE Health Care
- Exchange
- BYRN Nasdaq
- QURE Nasdaq
- Market Cap
- BYRN 670.5M
- QURE 725.4M
- IPO Year
- BYRN N/A
- QURE 2007
- Fundamental
- Price
- BYRN $23.65
- QURE $15.11
- Analyst Decision
- BYRN Strong Buy
- QURE Strong Buy
- Analyst Count
- BYRN 2
- QURE 10
- Target Price
- BYRN $41.50
- QURE $37.20
- AVG Volume (30 Days)
- BYRN 938.6K
- QURE 1.0M
- Earning Date
- BYRN 07-10-2025
- QURE 07-29-2025
- Dividend Yield
- BYRN N/A
- QURE N/A
- EPS Growth
- BYRN N/A
- QURE N/A
- EPS
- BYRN 0.62
- QURE N/A
- Revenue
- BYRN $103,528,000.00
- QURE $20,201,000.00
- Revenue This Year
- BYRN $37.49
- QURE N/A
- Revenue Next Year
- BYRN $21.56
- QURE $278.91
- P/E Ratio
- BYRN $37.98
- QURE N/A
- Revenue Growth
- BYRN 73.56
- QURE 6.30
- 52 Week Low
- BYRN $7.79
- QURE $4.45
- 52 Week High
- BYRN $34.78
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- BYRN 41.25
- QURE 54.26
- Support Level
- BYRN $20.22
- QURE $13.61
- Resistance Level
- BYRN $24.29
- QURE $15.49
- Average True Range (ATR)
- BYRN 2.11
- QURE 0.80
- MACD
- BYRN -0.33
- QURE 0.08
- Stochastic Oscillator
- BYRN 24.36
- QURE 68.27
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.